This project will be funded in whole or in part with federal funds from the NIAID, National Institutes of Health, and the Department of Health and Human Services.

"Leidos is proud to support NIAID and provide world-class innovations to treat and prevent infectious, immunologic and allergic diseases," said Liz Porter, Leidos Health Group president.

"For more than two decades, Leidos has supported the US biomedical research community.

"We are pleased to continue this journey and provide robust biomedical research to reinforce NIAID and its important mission."

Under the contract, Leidos is expected to provide a suite of biomedical, preclinical and development capabilities and capacity to the NIAID. These include chemistry manufacturing and control, non-clinical research, analytics, bioinformatics, computational biology, biostatistical services and both basic and mechanistic studies.

Leidos is also set to utilise its expertise in machine learning, natural language processing, high-level analytics, analytic programming languages and analysis methods.

VIEW ALL

Since 2000, Leidos has held several large medical product development contracts with federal government agencies to plan and manage biological and small molecule development programs for various disease indications. These include malaria, spinal muscular atrophy, anthrax, West Nile virus, HIV, polio, Candida and influenza.

Through these contracts, Leidos has provided services from initial concept to clinical implementation, including preclinical activities and clinical trial evaluation.

[Related: PM unveils $38bn ADF enhancement plan]